Abbott Laboratories' (ABT) underlying business momentum is intact heading into 2026 despite mixed Q3 results due to transient factors, RBC Capital said in a note Wednesday.

"ABT is a high-quality MedTech company, and as dips create opportunity with transitory Q3 headwinds, we reiterate our Outperform rating and $147 PT," RBC said

Abbott reported Q3 sales of $11.37 billion, missing the FactSet-polled consensus of $11.39 billion. Adjusted earnings climbed to $1.30 per share from $1.21 a year earlier, in line with the Street's expectation.

The company also narrowed its 2025 adjusted earnings guidance range to between $5.12 and $5.18 from $5.10 to $5.20 previously.

RBC noted that looking ahead to 2026 "management pointed to being comfortable" with the current Street estimates of high-single-digit revenue growth and double-digit growth EPS, "which are in-line with long-term sustainable growth targets for the company."

The RBC analysts said they remain positive on Abbott because of strong revenue underlying business momentum, strong capital allocation strategy and a "plethora of potential catalysts" for the stock in 2026.

Price: 129.18, Change: -0.27, Percent Change: -0.21